Eli M. Wallace - 11 Aug 2025 Form 3 Insider Report for BridgeBio Oncology Therapeutics, Inc. (HLXB)

Role
Chief Executive Officer, Director
Signature
/s/ Aaron Chan, Attorney-in-Fact
Issuer symbol
HLXB
Transactions as of
11 Aug 2025
Net transactions value
$0
Form type
3
Filing time
18 Aug 2025, 17:10:02 UTC
Next filing
28 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Wallace Eli M. Chief Executive Officer, Director BRIDGEBIO ONCOLOGY THERAPEUTICS, INC., 256 EAST GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO /s/ Aaron Chan, Attorney-in-Fact 18 Aug 2025 0001776352

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BBOT Stock Option (Right to Buy) 11 Aug 2025 Common Stock 620,618 $4.17 Direct F1
holding BBOT Stock Option (Right to Buy) 11 Aug 2025 Common Stock 37,172 $7.88 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of May 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date.
F2 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 4, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Exhibit 24 - Power of Attorney